DUBLIN – Shares in Argenx NV hit a 12-month high during early trading Monday on news that its fragment antibody, efgartigimod (ARGX-113), exhibited an efficacy signal in a small-scale, phase II trial in primary immune thrombocytopenia (ITP), which puts it on course for a pivotal phase III trial.